Topiramate-Actavis (Topiramate)

Therapeutic indications:

Epilepsy

Topiramate-Actavis is indicated in adults and children 2 years and over:

  • as monotherapy in patients with newly diagnosed epilepsy
  • for conversion to monotherapy in patients with epilepsy
  • as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.

Migraine

Topiramate-Actavis is indicated in adults for the prophylaxis of migraine headache.

HCP Guide
 
Patient Guide
 

Adverse event reporting

Please ensure any suspected adverse events and other safety information related to Topiramate-Actavis are reported through the appropriate channels, including Medsafe (https://pophealth.my.site.com/carmreportnz/s) and/or Teva’s Medical Information (email: Medinfo.ANZ@tevapharm.com), to support patient safety and continuous quality improvement.

Before prescribing, please review full Data Sheet available at:

https://www.medsafe.govt.nz/profs/Datasheet/t/topiramateactavistab.pdf

References: 

  1. Topiramate Actavis Data Sheet. Available at: https://www.medsafe.govt.nz/profs/Datasheet/t/topiramateactavistab.pdf (accessed July 2025).
  2. BPAC NZ. Contraception: which option for which patient? Available at: https://bpac.org.nz/2021/contraception/options.aspx (accessed July 2025).
  3. Topiramate-Actavis Consumer Medicine Information. Available at: https://www.medsafe.govt.nz/Consumers/CMI/t/topiramateactavis.pdf (accessed July 2025).